Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Position Boosted by Marshall Wace LLP

Marshall Wace LLP increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 608,706 shares of the company's stock after acquiring an additional 40,212 shares during the quarter. Marshall Wace LLP owned about 1.27% of Amphastar Pharmaceuticals worth $22,601,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Walleye Capital LLC acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth approximately $322,000. Barclays PLC boosted its position in shares of Amphastar Pharmaceuticals by 13.9% in the 4th quarter. Barclays PLC now owns 84,790 shares of the company's stock worth $3,148,000 after buying an additional 10,334 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 2.4% in the fourth quarter. Bessemer Group Inc. now owns 488,630 shares of the company's stock valued at $18,144,000 after purchasing an additional 11,609 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at approximately $3,450,000. Finally, Renaissance Group LLC lifted its position in shares of Amphastar Pharmaceuticals by 42.5% in the fourth quarter. Renaissance Group LLC now owns 99,572 shares of the company's stock valued at $3,697,000 after acquiring an additional 29,696 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded up $0.03 during trading on Friday, reaching $24.10. The stock had a trading volume of 70,825 shares, compared to its average volume of 463,348. The stock has a market cap of $1.14 billion, a PE ratio of 8.03, a P/E/G ratio of 2.19 and a beta of 0.79. The firm's 50 day moving average price is $27.17 and its two-hundred day moving average price is $36.73. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96.

Analyst Ratings Changes

Several equities analysts recently commented on AMPH shares. Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.